Multi-omics analyses reveal that cardiac senescence operates through distinct cellular programs rather than uniform deterioration. Some senescent cells temporarily support angiogenesis and repair following injury, while chronic senescent phenotypes drive inflammation and tissue remodeling through secreted inflammatory factors (SASP). This dual nature affects cardiomyocytes, endothelial cells, fibroblasts, and immune cells differently, creating context-dependent responses across the aging myocardium. The research demonstrates that senolytic drugs targeting harmful senescent cells and senomorphic compounds modulating their behavior can partially restore cardiac function in preclinical models. This fundamentally reframes how we understand cardiac aging—moving beyond viewing senescence as purely detrimental to recognizing its nuanced, sometimes beneficial roles. The implications are significant for cardiovascular disease prevention, particularly given that heart disease remains the leading cause of death globally. However, translating these mechanistic insights from laboratory models to clinical interventions remains challenging. The heterogeneous nature of cardiac senescence suggests that future therapies may need personalized approaches rather than blanket anti-aging strategies, potentially revolutionizing how we prevent and treat age-related heart conditions.